ArticleEBioMedicine2018
Screening of FDA-approved drugs identifies sutent as a modulator of UCP1 expression in brown adipose tissue.
Article in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 54 citations in OpenAlex.
- Determinants of activity of brown adipose tissue in lymphoma patients.Scientific reports · 2020Trial
- Article
- Inhibition of adipocyte RUNX1/2 enhances adipose tissue thermogenesis through distinct mechanisms.Nature communications · 2026Article
- Adipocyte Browning: A Promising Avenue in Anti-Obesity Therapy.International journal of molecular sciences · 2026Review
- No UCP1 in the kidney.Molecular metabolism · 2025Article
- The Role of Perirenal Adipose Tissue in Carcinogenesis-From Molecular Mechanism to Therapeutic Perspectives.Cancers · 2025Review
- Keys to the switch of fat burning: stimuli that trigger the uncoupling protein 1 (UCP1) activation in adipose tissue.Lipids in health and disease · 2024Review
- Thermogenic Fat as a New Obesity Management Tool: From Pharmaceutical Reagents to Cell Therapies.Biomedicines · 2024Review
- Unleashing the potential of adipose organoids: A revolutionary approach to combat obesity-related metabolic diseases.Theranostics · 2024Review
- Marine fungusFrontiers in pharmacology · 2024Article
- Modelling metabolic diseases and drug response using stem cells and organoids.Nature reviews. Endocrinology · 2022Review
- Single-cell sequencing unveils key contributions of immune cell populations in cancer-associated adipose wasting.Cell discovery · 2022Article
- Analysis of different adipose depot gene expression in cachectic patients with gastric cancer.Nutrition & metabolism · 2022Article
- Strategies for Browning Agent Delivery.Pharmaceutical research · 2021Review
- Improved Therapeutic Efficiency against Obesity through Transdermal Drug Delivery Using Microneedle Arrays.Pharmaceutics · 2021Article
- Optimized protocol for gene editing in adipocytes using CRISPR-Cas9 technology.STAR protocols · 2021Article
- Article
- Relieving lipid accumulation through UCP1 suppresses the progression of acute kidney injury by promoting the AMPK/ULK1/autophagy pathway.Theranostics · 2021Article
- Induction of UCP1 and thermogenesis by a small molecule via AKAP1/PKA modulation.The Journal of biological chemistry · 2020Article
- Elucidation of the roles of brown and brite fat genes: GPR120 is a modulator of brown adipose tissue function.Experimental physiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pharmacological activation of thermogenesis in brown adipose tissue has long been considered promising strategies to treat obesity. However, identification of safe and effective agents remains a challenge. In this study, we addressed this challenge by developing a cellular system with a fluorescence readout, and applied in a high-throughput manner to screen for FDA-approved drugs that may activate endogenous UCP1 expression in adipocytes.
methodsWe have generated a Ucp1-2A-GFP reporter mouse, in which GFP intensity serves as a surrogate of the endogenous expression level of UCP1 protein; and immortalized brown adipocytes were derived from this mouse model and applied in drug screening. Candidate drugs were further tested in mouse models either fed with normal chow or high fat diet to induce obesity.
findingsBy using the cellular screening platform, we identified a group of FDA-approved drugs that can upregulate UCP1 expression in brown adipocyte, including previously known UCP1 activators and new candidate drugs. Further studies focusing on a previously unreported drug-sutent, revealed that sutent treatment could increase the energy expenditure and inhibit lipid synthesis in mouse adipose and liver tissues, resulting in improved metabolism and resistance to obesity.
interpretationThis study offered an easy-to-use cellular screening system for UCP1 activators, and provided a candidate list of FDA-approved drugs that can potentially treat obesity. Further study of these candidates may shed new light on the drug discovery towards obesity. FUND: National Key Research and Development Program and the Strategic Priority Research Program of the Chinese Academy of Sciences, etc. (250 words).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.